Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Waldmann
T A
TA
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. tawald@helix.nih.gov
Dubois
S
S
Tagaya
Y
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D001327:Autoimmune Diseases / Q000628:therapy; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D019409:Interleukin-15 / Q000037:antagonists & inhibitors / Q000502:physiology*; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000502:physiology*; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000166:cytology* / Q000276:immunology*; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D019409:Interleukin-15; D007376:Interleukin-2